Landscape of KRAS G12C , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS -Mutated Cancers

Promising single-agent activity from sotorasib and adagrasib in -mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of -variant prevalence, genomic alterations, and the relationship between and immuno-oncology biomarkers is lacking. R...

Full description

Saved in:
Bibliographic Details
Published inJCO precision oncology Vol. 6; p. e2100245
Main Authors Salem, Mohamed E, El-Refai, Sherif M, Sha, Wei, Puccini, Alberto, Grothey, Axel, George, Thomas J, Hwang, Jimmy J, O'Neil, Bert, Barrett, Alexander S, Kadakia, Kunal C, Musselwhite, Laura W, Raghavan, Derek, Van Cutsem, Eric, Tabernero, Josep, Tie, Jeanne
Format Journal Article
LanguageEnglish
Published United States 01.05.2022
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Promising single-agent activity from sotorasib and adagrasib in -mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of -variant prevalence, genomic alterations, and the relationship between and immuno-oncology biomarkers is lacking. Retrospective analysis of deidentified records from 79,004 patients with various cancers who underwent next-generation sequencing was performed. Fisher's exact test evaluated the association between cancer subtypes and variants. Logistic regression assessed comutations with other oncogenes and the association between variants and immuno-oncology biomarkers. Of the 79,004 samples assessed, 13,758 (17.4%) harbored mutations, with 1,632 (11.9%) harboring and 12,126 (88.1%) harboring other variants ( ). Compared with across all tumor subtypes, was more prevalent in females (56% 51%, false discovery rate-adjusted value [FDR- ] = .0006), current or prior smokers (85% 56%, FDR- < .0001), and patients age > 60 years (73% 63%, FDR- ≤ .0001). The most frequent variants across all subtypes were G12D (29.5%), G12V (23.0%), G12C (11.9%), G13D (6.5%), and G12R (6.2%). was most prevalent in patients with non-small-cell lung cancer (9%), appendiceal (3.9%), colorectal (3.2%), tumor of unknown origin (1.6%), small bowel (1.43%), and pancreatic (1.3%) cancers. Compared with -mutated, -mutated tumors were significantly associated with tumor mutational burden-high status (17.9% 8.4%, odds ratio [OR] = 2.38; FDR- < .0001). -mutated tumors exhibited a distinct comutation profile from -mutated tumors, including higher comutations of (20.59% 5.95%, OR = 4.10; FDR- < .01) and (15.38% 4.61%, OR = 3.76; FDR- < .01). This study presents the first large-scale, pan-cancer genomic characterization of . The mutation was more prevalent in females and older patients and appeared to be associated with smoking status. tumors exhibited a distinct comutation profile and were associated with tumor mutational burden-high status.
AbstractList Promising single-agent activity from sotorasib and adagrasib in -mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of -variant prevalence, genomic alterations, and the relationship between and immuno-oncology biomarkers is lacking. Retrospective analysis of deidentified records from 79,004 patients with various cancers who underwent next-generation sequencing was performed. Fisher's exact test evaluated the association between cancer subtypes and variants. Logistic regression assessed comutations with other oncogenes and the association between variants and immuno-oncology biomarkers. Of the 79,004 samples assessed, 13,758 (17.4%) harbored mutations, with 1,632 (11.9%) harboring and 12,126 (88.1%) harboring other variants ( ). Compared with across all tumor subtypes, was more prevalent in females (56% 51%, false discovery rate-adjusted value [FDR- ] = .0006), current or prior smokers (85% 56%, FDR- < .0001), and patients age > 60 years (73% 63%, FDR- ≤ .0001). The most frequent variants across all subtypes were G12D (29.5%), G12V (23.0%), G12C (11.9%), G13D (6.5%), and G12R (6.2%). was most prevalent in patients with non-small-cell lung cancer (9%), appendiceal (3.9%), colorectal (3.2%), tumor of unknown origin (1.6%), small bowel (1.43%), and pancreatic (1.3%) cancers. Compared with -mutated, -mutated tumors were significantly associated with tumor mutational burden-high status (17.9% 8.4%, odds ratio [OR] = 2.38; FDR- < .0001). -mutated tumors exhibited a distinct comutation profile from -mutated tumors, including higher comutations of (20.59% 5.95%, OR = 4.10; FDR- < .01) and (15.38% 4.61%, OR = 3.76; FDR- < .01). This study presents the first large-scale, pan-cancer genomic characterization of . The mutation was more prevalent in females and older patients and appeared to be associated with smoking status. tumors exhibited a distinct comutation profile and were associated with tumor mutational burden-high status.
Author Puccini, Alberto
Van Cutsem, Eric
Musselwhite, Laura W
Kadakia, Kunal C
Tie, Jeanne
Tabernero, Josep
George, Thomas J
Grothey, Axel
Barrett, Alexander S
Sha, Wei
Raghavan, Derek
El-Refai, Sherif M
O'Neil, Bert
Salem, Mohamed E
Hwang, Jimmy J
Author_xml – sequence: 1
  givenname: Mohamed E
  surname: Salem
  fullname: Salem, Mohamed E
  organization: Levine Cancer Institute, Atrium Health, Charlotte, NC
– sequence: 2
  givenname: Sherif M
  orcidid: 0000-0003-2080-4172
  surname: El-Refai
  fullname: El-Refai, Sherif M
  organization: Tempus Labs Inc, Chicago, IL
– sequence: 3
  givenname: Wei
  surname: Sha
  fullname: Sha, Wei
  organization: Levine Cancer Institute, Atrium Health, Charlotte, NC
– sequence: 4
  givenname: Alberto
  orcidid: 0000-0002-2492-4043
  surname: Puccini
  fullname: Puccini, Alberto
  organization: University of Genoa, Ospedale Policlinico San Martino IRCCS, Genoa, Italy
– sequence: 5
  givenname: Axel
  surname: Grothey
  fullname: Grothey, Axel
  organization: West Cancer Center, Germantown, TN
– sequence: 6
  givenname: Thomas J
  orcidid: 0000-0002-6249-9180
  surname: George
  fullname: George, Thomas J
  organization: University of Florida, Gainesville, FL
– sequence: 7
  givenname: Jimmy J
  surname: Hwang
  fullname: Hwang, Jimmy J
  organization: Levine Cancer Institute, Atrium Health, Charlotte, NC
– sequence: 8
  givenname: Bert
  surname: O'Neil
  fullname: O'Neil, Bert
  organization: Tempus Labs Inc, Chicago, IL
– sequence: 9
  givenname: Alexander S
  surname: Barrett
  fullname: Barrett, Alexander S
  organization: Tempus Labs Inc, Chicago, IL
– sequence: 10
  givenname: Kunal C
  orcidid: 0000-0003-3574-4141
  surname: Kadakia
  fullname: Kadakia, Kunal C
  organization: Levine Cancer Institute, Atrium Health, Charlotte, NC
– sequence: 11
  givenname: Laura W
  surname: Musselwhite
  fullname: Musselwhite, Laura W
  organization: Levine Cancer Institute, Atrium Health, Charlotte, NC
– sequence: 12
  givenname: Derek
  orcidid: 0000-0002-7358-3994
  surname: Raghavan
  fullname: Raghavan, Derek
  organization: Levine Cancer Institute, Atrium Health, Charlotte, NC
– sequence: 13
  givenname: Eric
  orcidid: 0000-0002-6372-1230
  surname: Van Cutsem
  fullname: Van Cutsem, Eric
  organization: University Hospitals Gasthuisberg, Leuven & KULeuven, Leuven, Belgium
– sequence: 14
  givenname: Josep
  orcidid: 0000-0002-2495-8139
  surname: Tabernero
  fullname: Tabernero, Josep
  organization: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain
– sequence: 15
  givenname: Jeanne
  orcidid: 0000-0001-9244-2057
  surname: Tie
  fullname: Tie, Jeanne
  organization: Walter + Eliza Hall Institute of Medical Research, Melbourne, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35319967$$D View this record in MEDLINE/PubMed
BookMark eNo1kMtOwzAQRS0EolC6Yo_8AU2xJ06cLEMEpaKoiIdYVo4zAUNiV3G66Jofx2phNdIZ3YfuOTm2ziIhl5zNODB2_bSaAZ8xBiI5ImcgZBwJyMSITLz_YoHHHLhMT8koTmKe56k8Iz9LZWuv1Qapa-jDc_FC5xxKOqWF904bNWBN52hdZzQt2gF7NRhn_ZQGHV3YAHps94y-m-GTLrpua120stq17mNHb4zrVP-NvafGHgKix-2w9y2V1eFxQU4a1Xqc_N0xebu7fS3vo-VqviiLZaQ54zJqUoy1TGXG85SzptIAMQihMNeCawYVgtJKZUlVCakTltQsa1KokwAx6GBMrg6-m23VYb3e9CZU263_14BfpvVgyw
CitedBy_id crossref_primary_10_3390_cimb45030135
crossref_primary_10_3390_cancers14194828
crossref_primary_10_1016_j_ctrv_2024_102721
crossref_primary_10_1200_JCO_23_00434
crossref_primary_10_1186_s12967_023_04430_x
crossref_primary_10_1016_j_lungcan_2023_107293
crossref_primary_10_2217_fon_2022_1106
crossref_primary_10_3390_cancers16081447
crossref_primary_10_1158_1078_0432_CCR_22_3655
crossref_primary_10_1038_s41575_022_00736_1
crossref_primary_10_3390_cancers15205015
crossref_primary_10_1016_j_lungcan_2022_09_014
crossref_primary_10_1016_j_lungcan_2023_02_021
crossref_primary_10_3389_fmed_2024_1369136
crossref_primary_10_1016_j_cllc_2022_07_005
crossref_primary_10_1158_1535_7163_MCT_22_0810
crossref_primary_10_7759_cureus_27090
crossref_primary_10_1007_s00108_023_01651_6
crossref_primary_10_1186_s12964_023_01063_x
crossref_primary_10_1080_17512433_2022_2138339
crossref_primary_10_1038_s41591_024_02903_0
crossref_primary_10_1200_EDBK_438466
crossref_primary_10_3390_jcm11144098
crossref_primary_10_3389_fonc_2024_1357898
crossref_primary_10_1002_jlcr_4079
crossref_primary_10_3390_cancers14215430
crossref_primary_10_1186_s12014_023_09435_8
crossref_primary_10_1038_s41698_022_00334_z
crossref_primary_10_1177_17588359231216090
crossref_primary_10_1080_17474124_2024_2322648
crossref_primary_10_3390_cancers16051029
crossref_primary_10_1080_17476348_2023_2265810
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1200/PO.21.00245
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 2473-4284
ExternalDocumentID 35319967
Genre Journal Article
GroupedDBID 0R~
53G
ABDBF
ALMA_UNASSIGNED_HOLDINGS
C45
CGR
CUY
CVF
EBS
ECM
EIF
FBNNL
H13
NPM
O9-
OVD
RLZ
RUC
TEORI
ID FETCH-LOGICAL-c1017-f6e3c767819610fbc223244ae9c41c02be2acaa85bb47c505d08f62d5caae7672
IngestDate Sat Sep 28 08:18:43 EDT 2024
IsPeerReviewed true
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1017-f6e3c767819610fbc223244ae9c41c02be2acaa85bb47c505d08f62d5caae7672
ORCID 0000-0002-6249-9180
0000-0002-2492-4043
0000-0002-2495-8139
0000-0001-9244-2057
0000-0002-7358-3994
0000-0003-2080-4172
0000-0003-3574-4141
0000-0002-6372-1230
PMID 35319967
ParticipantIDs pubmed_primary_35319967
PublicationCentury 2000
PublicationDate 2022-05-00
PublicationDateYYYYMMDD 2022-05-01
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle JCO precision oncology
PublicationTitleAlternate JCO Precis Oncol
PublicationYear 2022
SSID ssj0002312176
Score 2.2328765
Snippet Promising single-agent activity from sotorasib and adagrasib in -mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However,...
SourceID pubmed
SourceType Index Database
StartPage e2100245
SubjectTerms Acetonitriles
Biomarkers, Tumor - genetics
Carcinoma, Non-Small-Cell Lung - genetics
Female
Genomics
Humans
Kelch-Like ECH-Associated Protein 1
Lung Neoplasms - genetics
Middle Aged
NF-E2-Related Factor 2
Piperazines
Proto-Oncogene Proteins p21(ras) - genetics
Pyrimidines
Retrospective Studies
Title Landscape of KRAS G12C , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS -Mutated Cancers
URI https://www.ncbi.nlm.nih.gov/pubmed/35319967
Volume 6
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYWKlVcqlZ90Zd86G3xNnGcOHtcVhT6YisKKjcUG1ukggStsheu_BD-KjO2k023tGp7SBTZsWN5Pk9m7HkQ8jZTiRQ2Myy1qWQiNxFTKkuZimyWSatTuNDaYj_bOxIfj9PjweCmZ7W0aNRIX93pV_I_VIUyoCt6yf4DZbtOoQCegb5wBwrD_a9o_Bn9dNGCCUW-TweTb8PdGKbMrfcw7SBP7hrnejycnLsIyjia1mbT7QfOgz0ccIjmbPgBHUZqNqu0j860XdYXaMIzd4az7iPsy6JxPU8RMuE4qBVwpzOMO-AT9wzr0Eu3jwO_I78HW58V8B9e-kHsnLMDY31ubAwXWdpepmN_KPXdlB0jX2hdumRUeMZg5k3d370AxbezFRwZx-W4kAkDHUj0WXKfpRoeu_PhO_k9d6msv85GPB798hYQ6_LCkT5BTjP2eT_-XLsSfLutWiNrMsfMIPthM-iHixQUg0KXBa9PGMq73kA2yP228YrG4iSXw4fkQVA56MTj5xEZmOoxue6wQ2tLkawUsUO36BI5NCCH9pCzRaEd_Qk3FHFDV3BDl7ihZeU_0OKGBtw8IUfvdw6neywk5GAaOTeDNZ1oCeINsO04skpzlMdFYcZaxDriyvBCF0WeKiWkBtn6NMptxk9TKDTQjj8l61VdmeeEKhXbRCqbFnkmIiFybiXnoKsIkRo-lpvkmZ-zk0sfdeWknc0Xv615STaWEHtF7llY5uY1yIyNeuModwt6s2ly
link.rule.ids 780
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Landscape+of+KRAS+G12C+%2C+Associated+Genomic+Alterations%2C+and+Interrelation+With+Immuno-Oncology+Biomarkers+in+KRAS+-Mutated+Cancers&rft.jtitle=JCO+precision+oncology&rft.au=Salem%2C+Mohamed+E&rft.au=El-Refai%2C+Sherif+M&rft.au=Sha%2C+Wei&rft.au=Puccini%2C+Alberto&rft.date=2022-05-01&rft.eissn=2473-4284&rft.volume=6&rft.spage=e2100245&rft_id=info:doi/10.1200%2FPO.21.00245&rft_id=info%3Apmid%2F35319967&rft_id=info%3Apmid%2F35319967&rft.externalDocID=35319967